THIEVON-WRIGHT CONSULTING GROUP

12 New Providence Road Watchung, NJ 07069

Office: 908.756.4411 **Fax:** 908.756.1122

www.cnssites.com info@cnssites.com

CBH HEALTH





Robert E. Litman, M.D. Khaled Khalafallah, M.D.

CBH Health

Gaithersburg, Maryland

PSYCHIATRY NEUROLOGY

INVESTIGATORS

Robert E. Litman, M.D., Medical Director and Principal Investigator at CBH Health, developed his interest in the treatment of Schizophrenia at Massachusetts General Hospital, where he completed his residency in Psychiatry. Shortly thereafter, he joined the Experimental Therapeutics Branch, National Institute of Mental Health, NIH, as a Senior Staff Fellow. After leaving the NIH, he formed his own clinical trials research organization. Since then he has conducted over 200 Phase I-IV clinical trials and has participated in many of the important advances in pharmacotherapy of Schizophrenia and other brain disorders. He serves as a consultant in psychopharmacology to many area hospitals, has over 30 academic publications, and speaks about new advances in the field of psychopharmacology and drug development for psychiatric illness. Dr. Litman is currently an Associate Professor of Psychiatry at Georgetown University Medical School and a Fellow and Diplomate of the American Board of Psychiatry and Neurology and Diplomate with added qualifications in Geriatric Psychiatry.

Khaled Khalafallah, M.D., is a board-certified Psychiatrist who serves as a Principal Investigator at CBH Health. He received his medical degree at the AlAzhar University Medical school in Cairo, Egypt in 1981, and completed his medical internship and psychiatric residency at Howard University Hospital in Washington, D.C. in 1999. Dr. Khalafallah has conducted Phase I-IV clinical trials in Schizophrenia, Bipolar and Alzheimer's disease.



STAFFING

Total Number of Staff 5	0
CRCs	3
Raters	5
Sub-Investigators	2
Recruitment Staff	7

Regulatory Affairs, Charge RN, Research Assistants, Research Technicians, Psychiatric Technicians, Driver, Support Staff

PATIENT DATABASE

PATIENT DATABASE	
Total Number of Subjects	2,750
Schizophrenic Subjects	1,980
Depressed Subjects	300
Anxiety Subject	
Alzheimer's Subjects	
STUDY EXPERIENCE	
Total	232
Phase I/Ib	
Phase II/III	
Schizophrenia (Stable)	33
Schizophrenia (Acute)	124
Bipolar	32
Depression	9
Anxiety Disorder	5
Alzheimer's Disease	5
Type 2 Diabetes	3
PATIENTS ENROLLED	
Schizophrenia (Acute)	2,117
Schizophrenia (Stable)	
Bipolar	
Depression	
'	

Alzheimer's Disease......53

CBH HEALTH

FACILITY

CBH Health is a state-of-the-art unit located in Gaithersburg, Maryland. The fully staffed inpatient unit holds 20 beds along with a ketamine infusion center, while the 3 bed outpatient suite has 2 exam rooms and additional lab facilities. The unit operates 24/7, with infrastructure, staff and equipment necessary to conduct double-blind placebo-controlled safety and efficacy trials. In addition to extensive experience with Phase II-III safety efficacy trials, since 2012, CBH has developed a distinct expertise in the conduct of Phase I and early Phase II clinical pharmacology, biomarker, and proof of principle (PoP) studies in special populations, including Schizophrenia, Bipolar Disorder, MDD, Anxiety and Dementia patients for putative antipsychotic, procognitive, and antidepressant compounds.